{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:05:51Z","timestamp":1791378351575,"version":"4.3.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12328-026-02378-1","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:17:55Z","timestamp":1782299875000},"page":"1185-1192","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two cases of durvalumab-induced Evans syndrome in biliary tract cancer"],"prefix":"10.1007","volume":"19","author":[{"given":"Ryo","family":"Komori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2713-4661","authenticated-orcid":false,"given":"Chikatoshi","family":"Katada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2378_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"2378_CR2","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30:1950\u20138.","journal-title":"Ann Oncol"},{"key":"2378_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S, et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). J Hepatobiliary Pancreat Sci. 2023;30:102\u201310.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2378_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"2378_CR5","first-page":"1045","volume":"402","author":"M Javle","year":"2023","unstructured":"Javle M, Borad MJ, Azad NS, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:1045\u201357.","journal-title":"Lancet"},{"key":"2378_CR6","unstructured":"Ministry of Health, Labour and Welfare [Internet]. Tokyo: Ministry of Health, Labour and Welfare; [cited 2025 Nov 9]. Available from: https:\/\/www.nanbyou.or.jp\/wp-content\/uploads\/upload_files\/File\/061-201704-kijyun.pdf"},{"key":"2378_CR7","unstructured":"Ministry of Health. Labour and Welfare [Internet]. Tokyo: Ministry of Health, Labour and Welfare; [cited 2025 Nov 9]. Available from: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000062437.html"},{"key":"2378_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archinte.1951.03810010058005","volume":"87","author":"RS Evans","year":"1951","unstructured":"Evans RS, Takahashi K, Duane RT, et al. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med. 1951;87:48\u201365.","journal-title":"AMA Arch Intern Med"},{"key":"2378_CR9","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/s41467-022-30863-x","volume":"13","author":"AJ Patel","year":"2022","unstructured":"Patel AJ, Willsmore ZN, Khan N, et al. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nat Commun. 2022;13:3148.","journal-title":"Nat Commun"},{"key":"2378_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12885-025-15391-3","volume":"26","author":"AJ Tan","year":"2025","unstructured":"Tan AJ, Lu JL, Li CX, et al. Hematological toxicity of immune checkpoint inhibitors: a pharmacovigilance study. BMC Cancer. 2025;26:23.","journal-title":"BMC Cancer"},{"key":"2378_CR11","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/iju5.12609","volume":"6","author":"S Kakita","year":"2023","unstructured":"Kakita S, Matsuo T, Ohki M, et al. Evans syndrome during pembrolizumab therapy for upper urinary tract cancer. IJU Case Rep. 2023;6:298\u2013301.","journal-title":"IJU Case Rep"},{"key":"2378_CR12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s12328-023-01767-0","volume":"16","author":"M Fukushima","year":"2023","unstructured":"Fukushima M, Tajima K, Sasaki R, et al. Evans\u2019 syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma. Clin J Gastroenterol. 2023;16:402\u20136.","journal-title":"Clin J Gastroenterol"},{"key":"2378_CR13","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"2378_CR14","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1182\/bloodadvances.2021005610","volume":"5","author":"B Fattizzo","year":"2021","unstructured":"Fattizzo B, Michel M, Giannotta JA, et al. Evans syndrome in adults: an observational multicenter study. Blood Adv. 2021;5:5468\u201378.","journal-title":"Blood Adv"},{"key":"2378_CR15","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","volume":"124","author":"W Barcellini","year":"2014","unstructured":"Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124:2930\u20136.","journal-title":"Blood"},{"key":"2378_CR16","doi-asserted-by":"publisher","first-page":"E243","DOI":"10.1002\/ajh.25212","volume":"93","author":"W Barcellini","year":"2018","unstructured":"Barcellini W, Zaninoni A, Fattizzo B, et al. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers. Am J Hematol. 2018;93:E243\u20136.","journal-title":"Am J Hematol"},{"key":"2378_CR17","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/rth2.12333","volume":"4","author":"CM Broome","year":"2020","unstructured":"Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis. Res Pract Thromb Haemost. 2020;4:628\u201335.","journal-title":"Res Pract Thromb Haemost"},{"key":"2378_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/blood.2020005674","volume":"136","author":"S Berentsen","year":"2020","unstructured":"Berentsen S, Barcellini W, D\u2019Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136:480\u20138.","journal-title":"Blood"},{"key":"2378_CR19","doi-asserted-by":"publisher","first-page":"102388","DOI":"10.1016\/j.bcmd.2019.102388","volume":"81","author":"G Ho","year":"2020","unstructured":"Ho G, Brunson A, Keegan THM, et al. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia. Blood Cells Mol Dis. 2020;81:102388.","journal-title":"Blood Cells Mol Dis"},{"key":"2378_CR20","doi-asserted-by":"publisher","first-page":"109450","DOI":"10.1016\/j.thromres.2025.109450","volume":"254","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yao W, Lang H, et al. Geographic and diagnostic variations in thrombosis risk among patients with immune thrombocytopenia: a systematic review and meta-analysis. Thromb Res. 2025;254:109450.","journal-title":"Thromb Res"},{"key":"2378_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3324\/haematol.12318","volume":"93","author":"MT Gladwin","year":"2008","unstructured":"Gladwin MT, Kato GJ. Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood). thickens! Haematol. 2008;93:1\u20133.","journal-title":"thickens! Haematol"},{"key":"2378_CR22","doi-asserted-by":"publisher","first-page":"15880","DOI":"10.1073\/pnas.1005743107","volume":"107","author":"TA Fuchs","year":"2010","unstructured":"Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107:15880\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2378_CR23","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/blood-2011-01-332676","volume":"118","author":"TA Fuchs","year":"2011","unstructured":"Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood. 2011;118:3708\u201314.","journal-title":"Blood"},{"key":"2378_CR24","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u201338.","journal-title":"Ann Oncol"},{"key":"2378_CR25","doi-asserted-by":"publisher","first-page":"1586426","DOI":"10.3389\/fimmu.2025.1586426","volume":"16","author":"JM Hernandez-Martinez","year":"2025","unstructured":"Hernandez-Martinez JM, Rios-Garcia E, Palomares-Palomares CB, et al. Immune hemolytic anemia associated with the use of immune checkpoint inhibitors: a scoping review. Front Immunol. 2025;16:1586426.","journal-title":"Front Immunol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-026-02378-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-026-02378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:42:58Z","timestamp":1791376978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-026-02378-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1007\/s12328-026-02378-1","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experi mentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008(5).","order":2,"name":"Ethics","label":"Human or animal rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients to be included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}